 |
|
|
|
 |
|
|
| Article 1 to 10 out of 55 concerning Genmab A/S
|
-
Genmab initiates Zalutumumab combination study in colorectal cancer
(03 Jun 2008)
Genmab A/S announced it has initiated a Phase I/II study of zalutumumab (HuMax-EGFr(TM)) in combination with irinotecan chemotherapy to treat colorectal cancer (CRC). The study will include a maximum of 97 patients who have failed standard ...
-
Novel insights into HuMax-EGFr mechanisms of action
(17 Apr 2008)
Genmab A/S announced new insights showing that HuMax-EGFr(TM) (zalutumumab) locks epidermal growth factor receptor (EGFr) molecules into a very compact, inactive conformation. The flexibility of the EGFr is central to its role in signaling, and ...
-
Genmab and PDL Biopharma close sale of antibody manufacturing facility
(17 Mar 2008)
Genmab A/S and PDL BioPharma, Inc. announced the closing of the previously announced transaction under which Genmab has acquired PDL's antibody manufacturing facility located in Brooklyn Park, Minnesota, USA for USD 240 million in cash. The ...
-
Genmab and Pepscan to identify human antibodies against intractable targets
(05 Mar 2008)
Genmab A/S and Pepscan announced the start of a research collaboration aimed at identifying fully human monoclonal antibodies against intractable disease targets. Intractable targets include those that are difficult to address using commonly ...
-
Purchase Agreement Between Genmab and PDL BioPharma for Antibody Manufacturing Facility Receives Antitrust Clearance
(28 Feb 2008)
Genmab A/S announced that the purchase agreement entered into between Genmab and PDL BioPharma, Inc. under which Genmab would acquire PDL's antibody manufacturing facility has received antitrust clearance from the US antitrust authorities under the ...
-
Genmab and PDL Biopharma sign purchase agreement for antibody manufacturing facility
(25 Feb 2008)
Genmab A/S and PDL BioPharma, Inc. announced that they have entered into an agreement under which Genmab would acquire PDL's antibody manufacturing facility located in Brooklyn Park, Minnesota, USA for USD 240 million to be paid in cash. The ...
-
Genmab reaches milestones in ofatumumab collaboration
(23 Jan 2008)
Genmab A/S (OMX: GEN) announced it has reached the second and third development milestones for ofatumumab (HuMax-CD20®) under the terms of its collaboration with GlaxoSmithKline (GSK). The second milestone payment of the collaboration of DKK 87.2 ...
-
Genmab wins Scrip's Biotech Company of the Year award
(06 Dec 2007)
Genmab A/S announced it has won the 2007 Scrip Biotech Company of the Year award. The award was presented December 4, 2007 at an awards ceremony and gala dinner at the London Hilton on Park Lane hotel.The award recognizes Genmab's accomplishments ...
-
Genmab and GlaxoSmithKline initiate ofatumumab rheumatoid arthritis phase III programme
(22 Nov 2007)
Genmab A/S and GlaxoSmithKline announced the initiation of the Phase III program with ofatumumab to treat rheumatoid arthritis (RA). The program will commence with two studies (GEN410/OFA110635 and GEN411/OFA110634) which will be conducted outside ...
-
Genmab provides insights into IgG4 antibodies
(17 Sep 2007)
Genmab A/S announced its scientists have discovered the basis for the instability of human IgG4 antibodies underlying their biological role in the immune system. In pre-clinical studies, Genmab discovered that IgG4 antibodies are dynamic and ...
Additional information
Genmab A/S
Copenhagen, Denmark
Company
|
|
|
|
|
|
Top
